Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/1470
Full metadata record
DC FieldValueLanguage
dc.contributorBergin, A.en_US
dc.contributorLuen, S.en_US
dc.contributorSavas, P.en_US
dc.contributorBoolell, Vishalen_US
dc.contributorCho, D.en_US
dc.contributorLynch, J.en_US
dc.contributorNott, L.en_US
dc.contributorStuart-Harris, R.en_US
dc.contributorTeo, Lee Naen_US
dc.contributorYap, S.en_US
dc.contributorLoi, S.en_US
dc.date.accessioned2020-01-08T04:24:54Z-
dc.date.available2020-01-08T04:24:54Z-
dc.date.issued2019-
dc.identifier.govdoc01450en_US
dc.identifier.urihttp://hdl.handle.net/11054/1470-
dc.description.abstractBackground Pertuzumab, when combined with trastuzumab and chemotherapy, is a highly active human epidermal growth factor receptor 2 (HER2), targeting agent in the neoadjuvant, adjuvant and first‐line metastatic HER2‐positive breast cancer setting. The efficacy of late‐line (after first/second‐line) pertuzumab in combination with trastuzumab and chemotherapy is unknown. Aims To establish pertuzumab efficacy by performing an audit of patients who received pertuzumab after first‐line HER2 directed therapy. We sought to establish whether efficacy differed by clinicopathological factors. Methods The primary endpoint was progression‐free survival (PFS) and the secondary endpoint, overall survival (OS). Clinicopathological factors, PFS and OS data were collated and clinicopathological factors associated with PFS were evaluated using Cox regression models. Results Fourteen women were identified. Six (43%) had hormone receptor (HR) negative and eight (57%) had HR‐positive, metastatic HER2‐positive breast cancer. Median follow up was 22.8 months, median prior lines of therapy were 5 (range: 1–9). Median time from diagnosis of metastatic disease to receiving pertuzumab was 4.5 years (range: 4.2–5.8). All patients received initial chemotherapy with pertuzumab and trastuzumab (taxane‐based 71%). Median PFS was 9 months (95% confidence interval [CI]: 7–not estimable [NE]) and median OS was not reached (95% CI, 16 months–NE). Univariable analysis demonstrated that HR‐negative patients had a significantly longer PFS than HR‐positive patients (hazard ratio = 0.11; 95% CI, 0.01–0.88; P = 0.04). Conclusion This small cases series reports a favorable PFS and OS for pertuzumab with trastuzumab and chemotherapy in the later line metastatic setting. This finding warrants further study.en_US
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2020-01-06T23:44:04Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2020-01-08T04:24:54Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2020-01-08T04:24:54Z (GMT). No. of bitstreams: 0 Previous issue date: 2019en
dc.relation.urihttps://doi.org/10.1111/ajco.13195en_US
dc.titleEfficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2‐positive metastatic breast cancer: an Australian case series.en_US
dc.typeJournal Articleen_US
dc.type.specifiedArticleen_US
dc.bibliographicCitation.titleAsia-Pacific Journal of Clinical Oncologyen_US
dc.bibliographicCitation.volume15en_US
dc.bibliographicCitation.issue6en_US
dc.bibliographicCitation.stpage377en_US
dc.bibliographicCitation.endpage382en_US
dc.subject.healththesaurusHER2 POSITIVEen_US
dc.subject.healththesaurusLATE LINE HER2-TARGETED THERAPYen_US
dc.subject.healththesaurusMETASTATIC BREAST CANCERen_US
dc.subject.healththesaurusPERTUZUMABen_US
dc.subject.healththesaurusTRASTUZUMABen_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.